Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components

• US 7,498,156 B2
• Filed: 06/15/2005
• Issued: 03/03/2009
• Est. Priority Date: 07/21/1998
• Status: Expired due to Fees

• Current Assignee: Terumo BCT Biotechnologies, LLC (Terumo Corporation), The Ohio State University Research Foundation
• Original Assignee: Caridianbct Biotechnologies LLC (Baxter International Inc.), The Ohio State University Research Foundation
• Inventors: Platz, Matthew S., Martin, Christopher B., Goodrich, Raymond P.
• Primary Examiner(s): Saucier; Sandra
• Assistant Examiner(s): HANLEY, SUSAN MARIE
• Application Number:
  US11/154,503
• Publication Number:
  US 20050282143A1
• Time in Patent Office: 1,357 Days
• Field of Search: 435/2, 435/251, 435/173.1, 514/251, 424529-534
• US Class Current: 435/173.1
• CPC Class Codes: A61K 31/50 Pyridazines; Hydrogenated pyridazines
• CPC Class Codes: A61K 41/17 by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
• CPC Class Codes: A61L 2/0011 using physical methods
• CPC Class Codes: A61L 2/0082 using chemical substances
• CPC Class Codes: A61M 1/3683 using photoactive agents

Abstract

This invention is directed towards a method of using visible light at wavelengths of at least 500 nm and above in combination with a sensitizer having a flavin moiety to reduce any pathogens that may be contained in blood and blood components. By exposing the blood and blood components to light of 500 nm and higher, only the sensitizer that is bound to nucleic acids of the pathogens will be activated, thus destroying the sensitizer-pathogenic nucleic acid complex. Because unbound sensitizer is not activated at this wavelength, damage to blood and blood components caused by photolysis of unbound sensitizer may be avoided.

Claims

1. A process for pathogen reduction of a fluid containing blood or blood products which may contain pathogens having nucleic acids comprising:

adding to the fluid a sensitizer containing a flavin moiety;

allowing the sensitizer to bind to the nucleic acid of the pathogens to make a fluid having bound sensitizer and unbound sensitizer; and

irradiating the fluid at a wavelength of 500 nm to 550 nm, wherein only the bound sensitizer is activated and the unbound sensitizer is not activated;

thereby reducing the number of pathogens in the fluid.

2. The process of claim 1 wherein the sensitizer containing a flavin moiety is an alloxazine.

3. The process of claim 2 wherein the alloxazine is riboflavin.

4. The process of claim 1, wherein the step of adding sensitizer further comprises adding sensitizer in a concentration between 50 μ

M and 200 μ

M.

5. The process of claim 1 wherein the fluid further comprises red blood cells.

6. The process of claim 1 wherein the fluid further comprises platelets.

7. The process of claim 1 wherein the fluid further comprises plasma.

8. The process of claim 1 wherein the step of irradiating further comprises removing light at wavelengths below 500 nm.

9. The process of claim 8 wherein the step of irradiating further comprises removing light at wavelengths above 525 nm.

10. The process of claim 8 wherein the step of irradiating further comprises removing light at wavelengths above 550 nm.